Canada's AmorChem launch­es $44.2M life sci­ence fund; Neon adds $36M, Mer­ck part­ner­ship in neoanti­gen dri­ve; CRISPR Ther­a­peu­tics files a CTA

→ Cana­di­an VC firm AmorChem Group has raised $44.2 mil­lion for its sec­ond life sci­ence fund. Backed by LPs in­clud­ing the Québec gov­ern­ment, Mon­tre­al …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.